Scientists discover harder-to-detect version of Omicron variant

Australia’s Queensland state has found a new omicron lineage in a traveler who arrived from South Africa, health authorities said Wednesday.

The new lineage has about half the gene variations of the original and can’t be detected with typical screening, the state’s acting chief health officer Peter Aitken told reporters. It was found in a traveler who had arrived from South Africa and tested positive for the coronavirus on Saturday, he said.

The new lineage has enough markers “to be able to classify it as omicron, but we don’t know enough about it as to what that means then as far as clinical severity, vaccine effectiveness,” Aitken said. “We now have omicron and omicron-like.”

The discovery comes as Queensland prepares to finally reopen its border to the rest of Australia ahead of schedule next Monday, as more than 80% of the eligible population will be fully vaccinated later this week.

The discovery may be a setback for scientists racing to understand the full impact of the omicron variant, including how virulent the strain is and whether vaccines are effective at reducing risk of severe disease. Although most genetic changes are innocuous as viruses mutate, some can make the mutant more adept at infecting cells, for example, or evading antibodies.

The new lineage has about half, or 14, of the genome mutations of the conventional omicron variant and doesn’t have the s-gene dropout feature, making it harder to track through PCR testing, Aitken said. The discovery is “going to lead to improvements in people recognizing potential spread of omicron in all communities,” he said.

  • Related Posts

    Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

    Andelyn bio sciences Inc, a leading patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Queen’s University to develop and manufacture AAV9-GM2, a gene therapy…

    Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

    Cellution Biologics Inc, a biologics company focused on developing, manufacturing and commercializing advanced human tissue-based products, announced the completion of its acquisition of the SimpliDerm hydrated human acellular dermal matrix…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

    Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

    Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

    Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

    ACB Gujarat arrested two FDA Officials red-handed in Bharuch accepting a bribe of ₹40,000

    ACB Gujarat arrested two FDA Officials red-handed in Bharuch accepting a bribe of ₹40,000

    US appeals court sides with Sun Pharma in Lipitor antitrust case

    US appeals court sides with Sun Pharma in Lipitor antitrust case

    Counterfeit Cosmetics Are No Longer a Fringe Problem: 4 in 10 Consumers Report Fake Products, Regulatory Silence Raises Serious Questions

    Counterfeit Cosmetics Are No Longer a Fringe Problem: 4 in 10 Consumers Report Fake Products, Regulatory Silence Raises Serious Questions

    Three arrested for illegal sale of mephentermine sulphate injections in Hyderabad

    Three arrested for illegal sale of mephentermine sulphate injections in Hyderabad